<DOC>
	<DOCNO>NCT00426803</DOCNO>
	<brief_summary>This trial conduct North America , Europe , Asia Oceania . The purpose study evaluate safety efficacy Recombinant Factor VIIa patient acute intracerebral bleeding .</brief_summary>
	<brief_title>Recombinant Factor VIIa Acute Intracerebral Haemorrhage</brief_title>
	<detailed_description />
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<criteria>Spontaneous intracranial haemorrhage ( ICH ) within 3 hour first symptom Patients secondary ICH Preexisting disability Haemophilia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>